-
Fined 18,000 yuan for producing and selling inferior drugs
Time of Update: 2021-03-26
Liaoning New Century Pharmaceuticals was rectified within a time limit due to three issues including the inconsistency between the actual storage conditions of some traditional Chinese medicinal materials and the regulations.
-
FDA concerns about the safety of Pfizer/Lilly's new painkiller tanezumab
Time of Update: 2021-03-26
”The US FDA added, “Although the two companies have proposed clinical risk mitigation strategies in the study, the risk of RPOA is still worrying, because a considerable number of patients with adverse events require total joint replacement.
-
Accelerated hospital admission after medical insurance? The top three soared 41 new blockbuster drugs such as Hengrui and Baekje PD-1!
Time of Update: 2021-03-26
Anti-tumor drugs are the "main force" entering the hospital Starting from March 1 this year, the 2020 National Medical Insurance Catalogue will be implemented.
Anti-tumor drugs are the "main force" entering the hospital Starting from March 1 this year, the 2020 National Medical Insurance Catalogue will be implemented.
-
Consumables in the eight regions of Henan have been bargained to start mass production
Time of Update: 2021-03-26
Medical Network News on March 25 Bargaining prices for supplies in eight regions On March 24, according to the news from Huazhao Equipment Network, the Xinxiang City Drugs and Medical Consumables Alliance Centralized Procurement Platform issued the "Notice on Online Quotations for the Centralized Procurement of Medical Consumables Alliance of Eight Cities (Counties) including Xinxiang City, Henan Province".
-
Arikayce approved in Japan: the first drug to treat nontuberculous mycobacterial lung disease caused by MAC
Time of Update: 2021-03-26
The study was carried out in patients with refractory NTM lung disease caused by MAC, and the results showed that the study reached the primary endpoint: at the 6th month of treatment, compared with a guideline-based multi-drug regimen (MDR), Arikayce once a day Combined treatment with MDR can significantly increase the conversion rate of sputum culture (p<0.
-
7 new domestically produced Class 1 anti-ED drugs are coming, and Yangtze River sprints for the first time!
Time of Update: 2021-03-26
The fourth domestic anti-ED oral PDE-5 inhibitor strikes, Haisco will win the first imitation A few days ago, Sichuan Haisco entered the administrative examination and approval stage with imitation 3 types of avanafil tablets, which is expected to be approved in the near future.
-
Macau suspends vaccination of mRNA COVID-19 vaccine today due to defective packaging
Time of Update: 2021-03-26
The vaccine (valid until June 2021) is related to the packaging defects of the vial caps.
Baintech and Fosun Pharma have initiated investigations into the cause of the problem and must immediately suspend the vaccination.
-
Hisun Pharmaceutical: Epirubicin Hydrochloride for Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-03-26
On March 23, Hisun Pharmaceutical announced that the company's epirubicin hydrochloride for injection has passed the quality and efficacy consistency evaluation of generic drugs.
On May 5, 2019, the State Food and Drug Administration accepted the company's application for the consistency evaluation of epirubicin hydrochloride for injection.
-
Pfizer said an oral new crown treatment drug has entered clinical trials
Time of Update: 2021-03-26
On March 24th, 23rd local time in the United States, the pharmaceutical company Pfizer announced on its official website that the oral new crown treatment drug PF-07321332 has entered the phase 1b clinical trial phase.
-
Novo Nordisk's high-dose semaglutide treatment application for diabetes is rejected by the FDA
Time of Update: 2021-03-26
0 mg once a week for treatment 2 Application for label extension for type-diabetes.
Although more information needs to be included in the resubmission, Novo Nordisk stated that the company believes that the completed clinical trial projects are sufficient to support semaglutide's label extension application.
-
Daiichi Sankyo mRNA vaccine DS-5670 Phase I/II clinical trial in Japan begins immunization
Time of Update: 2021-03-26
Recently, Daiichi Sankyo announced that the Phase I/II clinical trial of the novel coronavirus pneumonia (COVID-19) mRNA vaccine (DS-5670) in Japan has begun to vaccinate subjects.
Just recently, Moderna announced that its new-generation vaccine mRNA-1283 has been immunized in the first phase of clinical trials for the first batch of subjects.
-
Health Commission: 9 new confirmed cases, all imported from abroad
Time of Update: 2021-03-26
The latest situation of the novel coronavirus pneumonia epidemic as of 24:00 on March 22 The latest situation of the novel coronavirus pneumonia epidemic as of 24:00 on March 22 The
-
Physiological regulation mechanism of "dawn phenomenon" in diabetic patients
Time of Update: 2021-03-26
According to reports, the study reveals the regulation mechanism of insulin sensitivity rhythm in glucose metabolism, not only explaining physiological phenomena, but also providing mechanism explanations and treatment suggestions for the "dawn phenomenon" that plagues diabetic patients.
-
Shanghai passed local legislation: Chinese medicine is included in public health emergency management system
Time of Update: 2021-03-26
Encourage pharmaceutical manufacturers, operators of Chinese medicinal materials and Chinese medicinal pieces, medical institutions, and industry associations to establish an information traceability system in accordance with relevant laws, regulations and technical standards.
-
Yiling Pharmaceutical Dextromethorphan Hydrobromide Tablets Passed the Consistency Evaluation
Time of Update: 2021-03-26
On March 24, Yiling Pharmaceutical announced that it received the "Drug Supplementary Application Approval Notice" for dextromethorphan hydrobromide tablets approved and issued by the National Medical Products Administration.
At present, only 2 dextromethorphan hydrobromide tablets in China have passed the consistency evaluation (including the products approved by the company this time).
-
Health Commission: 11 new confirmed cases, all imported from abroad
Time of Update: 2021-03-26
As of 24:00 on March 24, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 165 confirmed cases (no severe cases), a total of 85,335 cured and discharged cases, and a total of 4,636 deaths.
-
More than 7,700 hospitals in my country have established an appointment diagnosis and treatment system
Time of Update: 2021-03-26
Medical Network News on March 24, National Health Commission’s Planning Development and Informatization Department Director Mao Qun’an said at a press conference of the National Health Commission on
-
How should traditional Chinese medicine companies spin off traditional Chinese medicines and transform them?
Time of Update: 2021-03-26
On March 22, Livzon Pharmaceutical announced that it plans to acquire 40% of Tianjin Tongrentang held by Tasly Holding Group as a financial investor for 724 million yuan.
-
Conba: 1mg finasteride tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-03-26
The sales of 1mg finasteride in the medical terminal market in 2019 was 47.
In 2019, the sales revenue of Hangzhou Kangenbei 1mg finasteride tablets was RMB 2.
73 million in research and development for the consistency evaluation of 1 mg finasteride tablets.
-
A complete analysis of the development of Shanghai's hospital drug market in 2020
Time of Update: 2021-03-26
Figure 5 The growth rate of different therapeutic areas in the Shanghai hospital drug market in 2020 Medical Network, March 24th, this issue of HMAS medical institution market analysis system in-depth deconstruction of the Shanghai hospital drug market in 2020: under the influence of the epidemic and large-scale procurement, how will the hospital market at all levels and categories perform in 2020?
